Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
SAN DIEGO, July 19, 2019 -- (Healthcare Sales & Marketing Network) -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen-Cilag International NV (Janssen) ... Biopharmaceuticals, Oncology, Drug Delivery, Regulatory Halozyme Therapeutics, Janssen, DARZALEX, daratumumab, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer & Oncology | European Medicines Agency (EMA) | Marketing | Myeloma | Pharmaceuticals